Rchr
J-GLOBAL ID:201201033895909920   Update date: Jun. 20, 2024

NAKASHIMA TAKU

ナカシマ タク | NAKASHIMA TAKU
Affiliation and department:
Homepage URL  (1): https://nrid.nii.ac.jp/ja/nrid/1000090643792/
Research field  (1): Respiratory medicine
Research keywords  (2): Pulmonary fibrosis, Interstitial lung diseases, bone marrow cells, tissue resident stem cells, lung cancer, lung injury ,  Bone marrow, Fibrosis, Pulmonary fibrosis, Interstitial pneumonia, Tissue resident stem cells, Lung cancer, Lung injury, Bone marrow transplantation
Research theme for competitive and other funds  (9):
  • 2023 - 2024 肺線維症における口腔内微生物叢変容の意義
  • 2024 - 骨髄細胞に潜在する質的障害が肺線維症に与える影響の解明
  • 2020 - 2023 Selection of bone marrow ALDH bright cells for treatment of pulmonary fibrosis focusing on changes in bone marrow characteristics
  • 2020 - 2021 腸内細菌叢の変化は肺線維症を悪化させるか
  • 2017 - 2020 ALDH activity-guided detection of lung tissue stem cells and its therapeutic use for pulmonary fibrosis
Show all
Papers (127):
  • Tanahashi, Hiroki, Iwamoto, Hiroshi, Yamaguchi, Kakuhiro, Sakamoto, Shinjiro, Horimasu, Yasushi, Masuda, Takeshi, Nakashima, Taku, Ohshimo, Shinichiro, Fujitaka, Kazunori, Hamada, Hironobu, et al. Lipocalin-2 as a prognostic marker in patients with acute exacerbation of idiopathic pulmonary fibrosis. RESPIRATORY RESEARCH. 2024. 25. 1
  • Miura, Shinichiro, Iwamoto, Hiroshi, Namba, Masashi, Yamaguchi, Kakuhiro, Sakamoto, Shinjiro, Horimasu, Yasushi, Masuda, Takeshi, Miyamoto, Shintaro, Nakashima, Taku, Ohshimo, Shinichiro, et al. High S100A9 level predicts poor survival, and the S100A9 inhibitor paquinimod is a candidate for treating idiopathic pulmonary fibrosis. BMJ OPEN RESPIRATORY RESEARCH. 2024. 11. 1
  • Shimoji, Kiyofumi, Nakashima, Taku, Masuda, Takeshi, Namba, Masashi, Sakamoto, Shinjiro, Yamaguchi, Kakuhiro, Horimasu, Yasushi, Mimae, Takahiro, Miyamoto, Shintaro, Iwamoto, Hiroshi, et al. Hypoxia-inducible factor 1a modulates interstitial pneumonia-mediated lung cancer progression. JOURNAL OF TRANSLATIONAL MEDICINE. 2023. 21. 1
  • Oda, Takashi, Iwamoto, Hiroshi, Takeno, Sachio, Kawasumi, Tomohiro, Takemoto, Kota, Nishida, Manabu, Chikuie, Nobuyuki, Horibe, Yuichiro, Yamaguchi, Kakuhiro, Sakamoto, Shinjiro, et al. Exhaled Nitric Oxide and Olfactory Dysfunction in Patients with Asthma: Association with Chronic Rhinosinusitis. MEDICINA-LITHUANIA. 2023. 59. 10
  • Yamada, Takahiro, Nakashima, Taku, Masuda, Takeshi, Sakamoto, Shinjiro, Yamaguchi, Kakuhiro, Horimasu, Yasushi, Miyamoto, Shintaro, Iwamoto, Hiroshi, Fujitaka, Kazunori, Hamada, Hironobu, et al. Intestinal overgrowth of Candida albicans exacerbates bleomycin-induced pulmonary fibrosis in mice with dysbiosis. JOURNAL OF PATHOLOGY. 2023. 261. 2. 227-237
more...
MISC (13):
  • 中尾聡志, 山口覚博, 鍵本篤志, 半田良憲, 坂本信二郎, 堀益靖, 益田武, 見前隆洋, 宮本真太郎, 中島拓, et al. Lower baseline levels of systemic soluble receptor for advanced glycation end products predict postoperative acute exacerbation of interstitial lung disease caused by lung cancer surgery. 日本呼吸器学会誌(Web). 2021. 10
  • 中西雄, 益田武, 山口覚博, 坂本信二郎, 堀益靖, 見前隆洋, 中島拓, 宮本真太郎, 津谷康大, 岩本博志, et al. NLRとAGRを用いたNSCLCに対するimmune checkpoint inhibitorの効果予測因子の検討. 日本肺癌学会総会号. 2020. 61st
  • 益田武, 中西雄, 山口覚博, 坂本信二郎, 堀益靖, 見前隆洋, 宮本真太郎, 中島拓, 津谷康大, 岩本博志, et al. Interstitial lung abnormalitiesの存在はPD-1/PD-L1阻害剤による肺障害に対するリスク因子となる. 日本肺癌学会総会号. 2019. 60th
  • 中西雄, 益田武, 山口覚博, 坂本信二郎, 堀益靖, 見前隆洋, 中島拓, 宮本真太郎, 津谷康大, 岩本博志, et al. 複数のバイオマーカーを用いたNSCLCに対するimmune checkpoint inhibitorの効果予測因子の検討. 日本肺癌学会総会号. 2019. 60th
  • Hiroshi Iwamoto, Yasushi Horimasu, Taku Nakashima, Shinichiro Ohshimo, Nobuhisa Ishikawa, Kazunori Fujitaka, Yoshinori Haruta, Hiroshi Murai, Noboru Hattori, Witold Mazur, et al. Decreased circulatory receptor for advanced glycation end-products is associated with poorer survival in patients with idiopathic pulmonary fibrosis. EUROPEAN RESPIRATORY JOURNAL. 2014. 44
more...
Books (9):
  • 今日の診断指針 第8版
    医学書院 2018
  • 間質性肺炎・肺線維症と類縁疾患
    中山書店 2018
  • 「間質性肺炎・肺線維症のトピックス」
    科学評論社 2018
  • 「ARDSのすべて」
    科学評論社 2018
  • 特発性間質性肺炎診断と治療の手引き
    2016
more...
Lectures and oral presentations  (207):
  • 非小細胞肺癌における免疫チェックポイント阻害剤に対する初期耐性の克服-PAI-1を標的とした治療方法の開発-
    (第64回日本肺癌学会総会 2311)
  • イピリムマブ併用/非併用複合免疫療法の毒性中止例における臨床転帰の比較ー多施設共同後向き研究ー
    (第64回日本肺癌学会総会 2311)
  • 進展型小細胞肺癌の下垂体転移に対し薬物療法を行い病勢制御し得た1例
    (第69回日本呼吸器中国・四国地方会 2023)
  • 外科的肺切除が奏効した器質化肺炎合併壊死性肺炎の一例
    (第69回日本呼吸器中国・四国地方会 2023)
  • Real worldにおけるイピリムマブ併用/非併用複合免疫療法におけるPD-L1 発現別の有効性・安全性の検討
    (第64回日本肺癌学会学術集会 2023)
more...
Education (2):
  • 2003 - 2008 Hiroshima University Graduate School, Division of Medical Sciences
  • 1995 - 2001 Hiroshima University Faculty of Medicine
Professional career (1):
  • MD, PhD. (Hiroshima University)
Work history (11):
  • 2024/04 - 現在 Hiroshima University Molecular and Internal Medicine Lecturer
  • 2024/04/01 - Graduate School of Biomedical and Health Sciences (Medicine) Dept. of Molecular and Internal Medicine Lecturer
  • 2017/10 - 2024/03 Hiroshima University Hospital Respiratory Medicine Clinical Lecturer
  • 2012/12 - 2024/03 Hiroshima University Hospital Hospital Research associate
  • 2012/07/01 - 2012/11/30 Hiroshima University Hospital Research associate
Show all
Awards (2):
  • 2009 - 広島大学広仁会 第27回広仁会賞
  • 2008/05 - American Thoracic Society ATS Travel Award Suppressor of cytokine signaling1 inhibits pulmonary inflammation and fibrosis
Association Membership(s) (4):
日本呼吸器内視鏡学会 ,  日本アレルギー学会 ,  日本呼吸器学会 ,  日本内科学会
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page